Intellia Therapeutics (LTS:0JBU) ROE % Adjusted to Book Value : -15.73% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics ROE % Adjusted to Book Value?

Intellia Therapeutics's ROE % for the quarter that ended in Mar. 2024 was -41.20%. Intellia Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was 2.62. Intellia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -15.73%.

Intellia Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Intellia Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics ROE % Adjusted to Book Value Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-12.57

-4.74

-3.98

-17.22

-15.42

Intellia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-12.36	-13.22	-16.84	-18.55	-15.73

Competitive Comparison of Intellia Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Intellia Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's ROE % Adjusted to Book Value falls into.

Intellia Therapeutics ROE % Adjusted to Book Value Calculation

Intellia Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-42.10%	/	2.73
	=	-15.42%

Intellia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-41.20%	/	2.62
	=	-15.73%

Intellia Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (LTS:0JBU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NTLA:USA 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics (LTS:0JBU) Headlines

No Headlines